Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes.
Tanios S Bekaii-SaabKrzysztof LachLing-I HsuMuriel SiadakMike StecherJames WardRachel BeckermanJohn H StricklerPublished in: The oncologist (2023)
While this study could not account for all confounding factors, in patients with RAS WT mCRC who received anti-EGFR therapy, HER2 overexpression/amplification was associated with worse PFS and ORR and may therefore predict poorer outcomes. HER2 testing is important to inform treatment decisions and could optimize outcomes for patients.
Keyphrases
- small cell lung cancer
- metastatic colorectal cancer
- epidermal growth factor receptor
- tyrosine kinase
- end stage renal disease
- ejection fraction
- newly diagnosed
- cell proliferation
- stem cells
- transcription factor
- mesenchymal stem cells
- metabolic syndrome
- patient reported outcomes
- glycemic control
- weight loss
- patient reported